Formulations of anti-rsv antibodies and methods of use thereof

An anti-RSV antibody formulation comprising:

• a) about 50 mg/mL to about 250 mg/mL of an anti-RSV antibody, or antigen-binding fragment thereof,
• b) about 5 mM to about 20 mM histidine;
• c) about 4% to about 8% (w/v) sucrose;
• d) an excipient selected from the group consisting of
• about 25 mM to about 75 mM of L-arginine or a pharmaceutically acceptable salt of L-arginine,
• about 25 mM to about 75 mM of L-lysine or a pharmaceutically acceptable salt of L-lysine,
• a mixture of about 25 mM to about 75 mM L-arginine or a pharmaceutically acceptable salt of L-arginine and about 25 mM to about 75 mM L-glutamate or a pharmaceutically acceptable salt of L-glutamate, and
• a mixture of about 25 mM to about 75 mM of L-arginine or a pharmaceutically acceptable salt of L-arginine and about 25 mM to about 75 mM L-lysine or a pharmaceutically acceptable salt of L-lysine;
• and
• e) about 0.01% to about 0.10% (w/v) polysorbate 80.